|Bid||0.55 x 0|
|Ask||0.59 x 0|
|Day's Range||0.55 - 0.60|
|52 Week Range||0.19 - 1.13|
|PE Ratio (TTM)||-4.25|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2.19|
CALGARY and SAN DIEGO, Oct. 11, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF), a biotech company developing REOLYSIN®, a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that Matt Coffey, Ph.D., President & Chief Executive Officer, will present a corporate overview and outline strategic objectives at the 2017 BIO Investor Forum.
Presenting clinical data of REOLYSIN ® in metastatic breast cancer and the Company's strategic objectives CALGARY and SAN DIEGO , Oct. 11, 2017 /CNW/ - Oncolytics Biotech ® Inc. (TSX: ONC) (OTCQX: ONCYF), ...
LONDON, UK / ACCESSWIRE / October 3, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...